Cara L. Haymaker Department of Translational Molecular Pathology University of Texas MD Anderson Cancer Center Biography Publications Institution JoVE Articles Cara L. Haymaker has not added a biography. If you are Cara L. Haymaker and would like to personalize this page please email our Author Liaison for assistance. Publications Hallmarks of Resistance to Immune-Checkpoint Inhibitors Cancer Immunology Research. Apr, 2022 | Pubmed ID: 35362046 Combined IL-2, Agonistic CD3 and 4-1BB Stimulation Preserve Clonotype Hierarchy in Propagated Non-small Cell Lung Cancer Tumor-infiltrating Lymphocytes Journal for Immunotherapy of Cancer. 02, 2022 | Pubmed ID: 35110355 Surgical Approach Does Not Influence Changes in Circulating Immune Cell Populations Following Lung Cancer Resection Lung Cancer (Amsterdam, Netherlands). 02, 2022 | Pubmed ID: 35038676 Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma Gastroenterology. Apr, 2022 | Pubmed ID: 34973294 Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma The Annals of Thoracic Surgery. 01, 2022 | Pubmed ID: 33971174 Effector Memory Cytotoxic CD3/CD8/CD45RO T Cells Are Predictive of Good Survival and a Lower Risk of Recurrence in Triple-negative Breast Cancer Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. Nov, 2021 | Pubmed ID: 34839351 Engineered T-cell Receptor T Cells for Cancer Immunotherapy Cancer Immunology Research. 11, 2021 | Pubmed ID: 34728535 Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 11, 2021 | Pubmed ID: 34426439 Pulmonary Resection for Tissue Harvest in Adoptive Tumor-infiltrating Lymphocyte Therapy: Safety and Feasibility Journal of Surgical Oncology. Sep, 2021 | Pubmed ID: 34057733 Randomized Phase II Trial of Lymphodepletion Plus Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes, with or Without Dendritic Cell Vaccination, in Patients with Metastatic Melanoma Journal for Immunotherapy of Cancer. 05, 2021 | Pubmed ID: 34021033 T-cell Agonists in Cancer Immunotherapy Journal for Immunotherapy of Cancer. 10, 2020 | Pubmed ID: 33020242 Peripheral Cytokines Are Not Influenced by the Type of Surgical Approach for Non-small Cell Lung Cancer by Four Weeks Postoperatively Lung Cancer (Amsterdam, Netherlands). 08, 2020 | Pubmed ID: 32619781 Neutrophil Expansion Defines an Immunoinhibitory Peripheral and Intratumoral Inflammatory Milieu in Resected Non-small Cell Lung Cancer: a Descriptive Analysis of a Prospectively Immunoprofiled Cohort Journal for Immunotherapy of Cancer. 04, 2020 | Pubmed ID: 32350118 Potential Clinical Application of Tumor-infiltrating Lymphocyte Therapy for Ovarian Epithelial Cancer Prior or Post-resistance to Chemotherapy Cancer Immunology, Immunotherapy : CII. Nov, 2019 | Pubmed ID: 31602489 Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in -Mutant Melanoma JCO Precision Oncology. 2018 | Pubmed ID: 30094412 4-1BB Agonist Focuses CD8(+) Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2017 | Pubmed ID: 28947567 Multifaceted Role of BTLA in the Control of CD8(+) T-cell Fate After Antigen Encounter Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2017 | Pubmed ID: 28754817 4-1BB-Enhanced Expansion of CD8(+) TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8(+) T Cells Cancer Immunology Research. Jun, 2017 | Pubmed ID: 28473315 Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion After Whole Brain Radiation and PD-1 Blockade Cancer Immunology Research. Feb, 2017 | Pubmed ID: 28062513 Novel Algorithmic Approach Predicts Tumor Mutation Load and Correlates with Immunotherapy Clinical Outcomes Using a Defined Gene Mutation Set BMC Medicine. Oct, 2016 | Pubmed ID: 27776519 पीढ़ी और प्राथमिक, घातक फुफ्फुस मेसोथेलियोमा ट्यूमर लाइनों का विस्तार Tamara M. Griffiths1, Carlos Ramos1, Cara L. Haymaker1 1Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center JoVE 63374 Cancer Research Vivo में एक टीकाकरण मॉडल का उपयोग कर प्रतिजन-विशिष्ट टी-सेल Cytolytic फ़ंक्शन का पता लगाने के लिए परख Cara L. Haymaker*1, Yared Hailemichael*1, Yi Yang2,3, Roza Nurieva2 1Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 2Department of Immunology, University of Texas MD Anderson Cancer Center, 3Department of Radiation Oncology, The Second Hospital of Jilin University JoVE 56255 Immunology and Infection
पीढ़ी और प्राथमिक, घातक फुफ्फुस मेसोथेलियोमा ट्यूमर लाइनों का विस्तार Tamara M. Griffiths1, Carlos Ramos1, Cara L. Haymaker1 1Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center JoVE 63374 Cancer Research
Vivo में एक टीकाकरण मॉडल का उपयोग कर प्रतिजन-विशिष्ट टी-सेल Cytolytic फ़ंक्शन का पता लगाने के लिए परख Cara L. Haymaker*1, Yared Hailemichael*1, Yi Yang2,3, Roza Nurieva2 1Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 2Department of Immunology, University of Texas MD Anderson Cancer Center, 3Department of Radiation Oncology, The Second Hospital of Jilin University JoVE 56255 Immunology and Infection
